© 2020 Israel China Biotechnology (ICB) Ltd. All Rights Reserved

 

Our vision is to build an Alibaba platform between Chinese market and Israeli MedTech by providing direct investment in Israeli cluster companies and leveraging the business potential by forming a partnership in China.

ICB wishes to build several clusters of MedTech start-ups through equity investments, and provide the Israeli start-ups with access to the huge Chinese healthcare market. ICB remains committed to integrity, honesty and fairness in all dealings with stakeholders. We aim to create for the companies in our platform a unique business opportunity in China by eliminating financial risk.

Values 

We pride ourselves on our diverse and experienced teams both in Israel and in China, who, coupled with their enthusiastic and committed approach, provide an inimitable and dedicated experience to our platform companies.

As we strive for excellence, with passion for success, we will encourage entrepreneurship among our cluster start-ups, as we pursue projects with a sense of urgency and total dedication to results.

We promote open communication and professional development, as we work toward shared goals throughout our investment platform and organizational structure.

Our precise investment process and long experience of Chinese local industry experience in the Chinese biomedical ecosystem render us best equipped to build the platform to the huge Chinese healthcare market.

Company Profile

ICB (previously named BSP) has been in the biotech industry for many years. In 2017, Mr. Huang Qingxi, a Chinese investor, took control of the company, and the board of directors shifted priority to become an investment company in the biomedical field. 

ICB Biotechnology Investments Ltd. (TASE:ICB) shifted business strategy in 2018 to become a leading high-tech healthcare platform in Israeli medical companies that directly provides equity funding to pave the way for Israeli companies into China, the biggest emerging market in the world.

 

Backed by prominent partners in China, ICB is a public company traded under the ICB symbol since March 2018 in the Tel Aviv Stock Exchange.

The management consists of skillful operational entrepreneurs who have extensive experience in investment, management, private equity, and venture capital. Our team leverages knowledge, connections, network and support to assist our partners and portfolio companies in seizing new opportunities for substantial growth.

Business Strategy 

ICB creates high value for companies with proven technology that are ready or close to ready to engage in the Chinese market for their technology. ICB invests in companies interested in partnering with our Chinese strengths through partnership. We leverage business and government connections alongside long-term relations to enable our platform cluster companies to establish production and manufacturing and distribution and R&D in China under favorable conditions to Israeli start-ups and at low costs. Both Israeli companies and the Chinese market will benefit from our unique investment platform and strategic partnerships.

Our Goal 

Invest in technologies by cluster in a platform with high market potential through partnership in China.

Focused Investment

Connect leading strategic partners to build clusters of investment in synergistic areas. 

Investment Policy

ICB will invest in Israeli healthcare technology companies with the potential to become major players in China. We will capitalize on the demands of the Chinese economy with our unique know-how and networking in China. Our understanding of Chinese market trends enables us to identify unique business and financial platform opportunities and facilitate fruitful matches. Our multicultural Chinese/Israeli team will consistently create success stories by investing in:

  • Companies with proven preliminary feasibility and an excellent chance of success

  • Companies with great potential in the Chinese market

  • Companies expected to produce real value in relatively short time

 

Board of Directors 

MR. HUANG QINGXI

CHAIRMAN OF BOARD OF DIRECTORS, PRESIDENT

MRS. OSNAT HILLEL FAIN
EXTERNAL DIRECTOR
PROF. MICHAEL ELDAR
EXTERNAL DIRECTOR 
PROF. CHAIM LOTAN
DIRECTOR
MR. BARAK DVIR
DIRECTOR 
MR. EITAN SEGAL
DIRECTOR & VP BUSINESS DEV.
MR. ANDREW ZHANG
DIRECTOR & CEO

ICB on Tel aviv stock exchange

Click this to view our wholly owned company BSP Medical Investors Presentation (Hebrew)

Management

MR. ANDREW ZHANG

CEO

MR. EITAN SEGAL

VP, BUISNESS DEV.

MR. GUY GOLDIN

CFO

 
 

Investments

ICB is investment portfolio includes the these ground-breaking technology companies. Together with CIB, ICB's major shareholder, we are proud to have formed joint ventures (JV) in China with most of our invested companies, opening the door for them to the huge Chinese market and to new investors.

BSP Medical
BestBrain 
BioSert
Defibris
Pulse-Or
BiFlow Medical
WellBe
Novomic
RMDY Health
Wear2b
ShizimXL-ICB
Contact Us Now